Our co-founder, professor Karl-Göran Tranberg, began innovative scientific research into how precise laser-generated “low temperature-long time” thermal ablation (imILT), of cancer tumors triggered the immune system to track and kill cancer cells throughout the body, the so called abscopal effect.

Through this research, CLS gained significant knowledge and experience with treating/killing prostate cancer tumors under MRI-guidance using focal laser ablation.  Clinical trials have been conducted and published, some are ongoing, and several new studies are planned for the near future.

CLS is currently conducting clinical studies for MR-US fusion-guided focal laser ablation for the treatment of low-to-medium risk prostate cancer. This new image-guidance is designed to enable urologist physicians to treat patients in a urology clinic or office, and not require a hospital visit or stay. Fusion guidance is already successfully being used for targeted prostate biopsies and focal therapies.